The	O
normal	O
cell	O
cycle	O
activation	O
program	O
is	O
exploited	O
during	O
the	O
infection	O
of	O
quiescent	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
by	O
Epstein-Barr	O
virus	O
.	O

B	B-cell_type
lymphocytes	I-cell_type
in	O
the	O
peripheral	O
circulation	O
are	O
maintained	O
in	O
a	O
non-proliferative	O
state	O
.	O

Antigen	O
recognition	O
stimulates	O
limited	O
proliferation	O
,	O
whereas	O
infection	O
with	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
results	O
in	O
continual	O
proliferation	O
and	O
the	O
outgrowth	O
of	O
immortal	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Because	O
it	O
is	O
not	O
clear	O
at	O
which	O
point	O
in	O
cell	O
cycle	O
the	O
peripheral	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
are	O
arrested	O
,	O
we	O
characterized	O
the	O
expression	O
of	O
several	O
cell	B-DNA
cycle-associated	I-DNA
genes	I-DNA
in	O
quiescent	B-cell_type
and	I-cell_type
stimulated	I-cell_type
cells	I-cell_type
.	O

We	O
show	O
that	O
the	O
expression	O
of	O
four	O
cell	B-DNA
genes	I-DNA
,	O
cdc-2	B-DNA
,	O
cyclin	B-DNA
E	I-DNA
,	O
CD23	B-DNA
,	O
and	O
cyclin	B-DNA
D2	I-DNA
,	O
are	O
up-regulated	O
approximately	O
100-fold	O
as	O
a	O
result	O
of	O
EBV-mediated	O
immortalization	O
.	O

Because	O
these	O
genes	O
play	O
a	O
positive	O
role	O
in	O
cell	O
proliferation	O
,	O
we	O
suggest	O
that	O
this	O
regulatory	O
switch	O
contributes	O
to	O
controlling	O
entry	O
into	O
the	O
cell	O
cycle	O
.	O

Transient	O
stimulation	O
of	O
quiescent	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
with	O
either	O
a	O
cocktail	O
of	O
anti-CD40	B-protein
,	O
anti-IgM	B-protein
,	O
and	O
IL4	B-protein
,	O
or	O
EBV	O
results	O
in	O
the	O
rapid	O
expression	O
of	O
the	O
same	O
four	O
genes	O
,	O
suggesting	O
that	O
,	O
after	O
infection	O
,	O
EBV	O
exploits	O
the	O
normal	O
program	O
of	O
B-lymphocyte	B-cell_type
cell	O
cycle	O
activation	O
.	O

[	NULL
CANCER	NULL
RESEARCH	NULL
55	NULL
,	NULL
4784-4787	NULL
,	NULL
November	NULL
1	NULL
,	NULL
1995	NULL
]	NULL
Advances	NULL
in	NULL
Brief	NULL
The	NULL
Normal	NULL
Cell	NULL
Cycle	NULL
Activation	NULL
Program	NULL
Is	NULL
Exploited	NULL
during	NULL
the	NULL
Infection	NULL
of	NULL
Quiescent	NULL
B	NULL
Lymphocytes	NULL
by	NULL
Epstein-Barr	NULL
Virus	NULL
!	NULL

Martine	NULL
Hollyoake	NULL
,	NULL
Albert	NULL
Stiihler	NULL
,	NULL
Paul	NULL
Farrell	NULL
,	NULL
John	NULL
Gordon	NULL
,	NULL
and	NULL
Alison	NULL
Sinclair	NULL
Ludwig	NULL
Institure	NULL
for	NULL
Cancer	NULL
Research	NULL
,	NULL
St.	NULL
Mary	NULL
's	NULL
Hospital	NULL
Medical	NULL
School	NULL
,	NULL
Norfolk	NULL
Place	NULL
,	NULL
London	NULL
W2	NULL
IPG	NULL
[	NULL
M.	NULL
H.	NULL
,	NULL
A.	NULL
St.	NULL
,	NULL
P.	NULL
F.	NULL
,	NULL
A.	NULL
Si	NULL
}	NULL
,	NULL
and	NULL
Department	NULL
of	NULL
Immunology	NULL
,	NULL
The	NULL
Medical	NULL
School	NULL
,	NULL
Vincent	NULL
Drive	NULL
,	NULL
Birmingham	NULL
B15	NULL
2TT	NULL
[	NULL
J.	NULL
G.	NULL
]	NULL
,	NULL
England	NULL
Abstract	NULL
B	NULL
lymphocytes	NULL
in	NULL
the	NULL
peripheral	NULL
circulation	NULL
are	NULL
maintained	NULL
in	NULL
a	NULL
non-proliferative	NULL
state	NULL
.	NULL

Antigen	NULL
recognition	NULL
stimulates	NULL
limited	NULL
proliferation	NULL
,	NULL
whereas	NULL
infection	NULL
with	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
results	NULL
in	NULL
continual	NULL
proliferation	NULL
and	NULL
the	NULL
outgrowth	NULL
of	NULL
immortal	NULL
cell	NULL
lines	NULL
.	NULL

Because	NULL
it	NULL
is	NULL
not	NULL
clear	NULL
at	NULL
which	NULL
point	NULL
in	NULL
cell	NULL
cycle	NULL
the	NULL
peripheral	NULL
B	NULL
lymphocytes	NULL
are	NULL
arrested	NULL
,	NULL
we	NULL
characterized	NULL
the	NULL
expression	NULL
of	NULL
several	NULL
cell	NULL
cycle-associated	NULL
genes	NULL
in	NULL
quiescent	NULL
and	NULL
stimulated	NULL
cells	NULL
.	NULL

We	NULL
show	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
four	NULL
cell	NULL
genes	NULL
,	NULL
edc-2	NULL
,	NULL
cyclin	NULL
E	NULL
,	NULL
CD23	NULL
,	NULL
and	NULL
cyclin	NULL
D2	NULL
,	NULL
are	NULL
up-regulated	NULL
approximately	NULL
100-fold	NULL
as	NULL
a	NULL
result	NULL
of	NULL
EBV-mediated	NULL
immortalization	NULL
.	NULL

Because	NULL
these	NULL
genes	NULL
play	NULL
a	NULL
positive	NULL
role	NULL
in	NULL
cell	NULL
proliferation	NULL
,	NULL
we	NULL
suggest	NULL
that	NULL
this	NULL
regulatory	NULL
switch	NULL
contributes	NULL
to	NULL
controlling	NULL
entry	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Transient	NULL
stimulation	NULL
of	NULL
quiescent	NULL
B	NULL
lymphocytes	NULL
with	NULL
either	NULL
a	NULL
cocktail	NULL
of	NULL
anti-CD40	NULL
,	NULL
anti-IgM	NULL
,	NULL
and	NULL
IL4	NULL
,	NULL
or	NULL
EBV	NULL
results	NULL
in	NULL
the	NULL
rapid	NULL
expression	NULL
of	NULL
the	NULL
same	NULL
four	NULL
genes	NULL
,	NULL
suggesting	NULL
that	NULL
,	NULL
after	NULL
infection	NULL
,	NULL
EBV	NULL
exploits	NULL
the	NULL
normal	NULL
program	NULL
of	NULL
B-lymphocyte	NULL
cell	NULL
cycle	NULL
activation	NULL
.	NULL

Introduction	NULL
The	NULL
B	NULL
lymphocytes	NULL
found	NULL
in	NULL
the	NULL
peripheral	NULL
circulation	NULL
exist	NULL
in	NULL
a	NULL
quiescent	NULL
state	NULL
and	NULL
require	NULL
stimulation	NULL
with	NULL
a	NULL
specific	NULL
antigen	NULL
to	NULL
enter	NULL
into	NULL
the	NULL
cell	NULL
division	NULL
cycle	NULL
and	NULL
to	NULL
proliferate	NULL
.	NULL

Although	NULL
much	NULL
progress	NULL
has	NULL
been	NULL
made	NULL
toward	NULL
elucidating	NULL
the	NULL
signal	NULL
transduction	NULL
events	NULL
arising	NULL
from	NULL
stimulation	NULL
of	NULL
the	NULL
B-cell	NULL
receptor	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

1	NULL
)	NULL
,	NULL
litle	NULL
is	NULL
known	NULL
about	NULL
the	NULL
molecular	NULL
mechanisms	NULL
that	NULL
maintain	NULL
the	NULL
quiescent	NULL
status	NULL
B	NULL
lymphocytes	NULL
,	NULL
or	NULL
about	NULL
the	NULL
changes	NULL
necessary	NULL
to	NULL
facilitate	NULL
cell	NULL
cycle	NULL
entry	NULL
after	NULL
stimulation	NULL
.	NULL

Recent	NULL
progress	NULL
in	NULL
dissecting	NULL
cell	NULL
cycle	NULL
controls	NULL
has	NULL
shown	NULL
that	NULL
there	NULL
are	NULL
many	NULL
routes	NULL
to	NULL
exit	NULL
from	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
,	NULL
and	NULL
it	NULL
is	NULL
not	NULL
clear	NULL
at	NULL
which	NULL
stage	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
B	NULL
lymphocytes	NULL
became	NULL
growth	NULL
arrested	NULL
during	NULL
their	NULL
differentiation	NULL
into	NULL
peripheral	NULL
cells	NULL
.	NULL

Quiescent	NULL
B	NULL
lymphocytes	NULL
can	NULL
also	NULL
be	NULL
activated	NULL
after	NULL
infection	NULL
with	NULL
the	NULL
DNA	NULL
tumor	NULL
virus	NULL
EBV	NULL
;	NULL
infection	NULL
causes	NULL
cells	NULL
to	NULL
proliferate	NULL
,	NULL
and	NULL
a	NULL
proportion	NULL
of	NULL
the	NULL
infected	NULL
cells	NULL
continue	NULL
to	NULL
divide	NULL
indefinitely	NULL
,	NULL
resulting	NULL
in	NULL
the	NULL
outgrowth	NULL
of	NULL
immortal	NULL
LCLs	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Mutagenesis	NULL
experiments	NULL
have	NULL
shown	NULL
that	NULL
at	NULL
least	NULL
six	NULL
viral	NULL
genes	NULL
are	NULL
necessary	NULL
for	NULL
EBV-mediated	NULL
immortalization	NULL
(	NULL
5	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
a	NULL
complex	NULL
series	NULL
of	NULL
events	NULL
are	NULL
needed	NULL
to	NULL
override	NULL
normal	NULL
growth	NULL
controls	NULL
.	NULL

The	NULL
simplest	NULL
scenario	NULL
to	NULL
account	NULL
for	NULL
the	NULL
quiescent	NULL
phenotype	NULL
of	NULL
primary	NULL
B	NULL
lymphocytes	NULL
would	NULL
be	NULL
the	NULL
absence	NULL
of	NULL
essential	NULL
positive	NULL
regulators	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
,	NULL
such	NULL
as	NULL
cyclins	NULL
or	NULL
edks	NULL
.	NULL

We	NULL
recently	NULL
Received	NULL
8/16/95	NULL
;	NULL
accepted	NULL
9/21/95	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
Leukaemia	NULL
Research	NULL
Fund	NULL
project	NULL
grant	NULL
to	NULL
A.	NULL
S.	NULL
and	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Medical	NULL
Research	NULL
Council	NULL
(	NULL
United	NULL
Kingdom	NULL
)	NULL
and	NULL
the	NULL
EC	NULL
BIOTECH	NULL
program	NULL
to	NULL
J.	NULL
G.	NULL
*	NULL
To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

Phone	NULL
:	NULL
0171-724-5522	NULL
,	NULL
extension	NULL
210	NULL
;	NULL
Fax	NULL
:	NULL
0171-724-8586	NULL
;	NULL
E-mail	NULL
:	NULL
afs30	NULL
@	NULL
dka.sm.ic.ac.uk	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
EBV	NULL
,	NULL
Epstein-Barr	NULL
virus	NULL
;	NULL
LCL	NULL
,	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
;	NULL
cdk	NULL
,	NULL
cyclin-dependent	NULL
kinase	NULL
;	NULL
IL-4	NULL
,	NULL
interleukin	NULL
4	NULL
;	NULL
RT-PCR	NULL
,	NULL
reverse	NULL
transcription	NULL
PCR	NULL
.	NULL

demonstrated	NULL
that	NULL
cyclin	NULL
D2	NULL
mRNA	NULL
is	NULL
undetectable	NULL
in	NULL
quiescent	NULL
primary	NULL
B	NULL
lymphocytes	NULL
,	NULL
but	NULL
it	NULL
is	NULL
expressed	NULL
at	NULL
high	NULL
levels	NULL
after	NULL
infection	NULL
with	NULL
EBV	NULL
(	NULL
6-8	NULL
)	NULL
.	NULL

Because	NULL
the	NULL
D-type	NULL
cyclins	NULL
,	NULL
in	NULL
conjunction	NULL
with	NULL
edk4	NULL
and	NULL
cdk6	NULL
,	NULL
act	NULL
as	NULL
positive	NULL
regulators	NULL
of	NULL
progression	NULL
through	NULL
G	NULL
,	NULL
(	NULL
9-11	NULL
)	NULL
,	NULL
the	NULL
increased	NULL
expression	NULL
of	NULL
cyclin	NULL
D2	NULL
in	NULL
EBV-infected	NULL
B	NULL
lymphocytes	NULL
might	NULL
have	NULL
a	NULL
direct	NULL
influence	NULL
on	NULL
their	NULL
proliferation	NULL
status	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
characterize	NULL
the	NULL
expression	NULL
of	NULL
several	NULL
cell	NULL
cycle	NULL
control	NULL
genes	NULL
in	NULL
quiescent	NULL
B	NULL
lymphocytes	NULL
and	NULL
investigate	NULL
how	NULL
these	NULL
are	NULL
altered	NULL
in	NULL
response	NULL
to	NULL
stimulation	NULL
with	NULL
physiological	NULL
agents	NULL
or	NULL
infection	NULL
with	NULL
EBV	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
cyclin	NULL
D2	NULL
,	NULL
we	NULL
chose	NULL
four	NULL
cell	NULL
genes	NULL
involved	NULL
in	NULL
cell	NULL
cycle	NULL
control	NULL
[	NULL
¢de-2	NULL
,	NULL
cyclin	NULL
E	NULL
,	NULL
c-myc	NULL
,	NULL
and	NULL
B-myb	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

12	NULL
)	NULL
]	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
B-lymphocyte	NULL
activation	NULL
antigen	NULL
CD23	NULL
.	NULL

In	NULL
its	NULL
secreted	NULL
form	NULL
,	NULL
CD23	NULL
acts	NULL
as	NULL
an	NULL
autocrine	NULL
growth	NULL
factor	NULL
for	NULL
LCLs	NULL
(	NULL
13	NULL
)	NULL
,	NULL
and	NULL
as	NULL
a	NULL
trans-membrane	NULL
protein	NULL
it	NULL
has	NULL
the	NULL
potential	NULL
to	NULL
act	NULL
as	NULL
a	NULL
receptor	NULL
;	NULL
CD21	NULL
has	NULL
been	NULL
identified	NULL
as	NULL
one	NULL
of	NULL
its	NULL
counter	NULL
structures	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Our	NULL
data	NULL
show	NULL
that	NULL
stimulation	NULL
with	NULL
physiological	NULL
ligands	NULL
or	NULL
infection	NULL
with	NULL
EBV	NULL
up-regulates	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
same	NULL
genes	NULL
,	NULL
implying	NULL
that	NULL
the	NULL
lack	NULL
of	NULL
expression	NULL
of	NULL
these	NULL
genes	NULL
is	NULL
necessary	NULL
to	NULL
maintain	NULL
the	NULL
quiescent	NULL
status	NULL
of	NULL
peripheral	NULL
B	NULL
lymphocytes	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Cell	NULL
Culture	NULL
.	NULL

Primary	NULL
B	NULL
lymphocytes	NULL
were	NULL
isolated	NULL
from	NULL
adult	NULL
peripheral	NULL
blood	NULL
by	NULL
positive	NULL
selection	NULL
with	NULL
pan	NULL
B-dynabeads	NULL
essentially	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
7	NULL
,	NULL
15	NULL
)	NULL
.	NULL

The	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
LCL	NULL
#	NULL
3	NULL
was	NULL
generated	NULL
by	NULL
EBV-mediated	NULL
immortalization	NULL
of	NULL
an	NULL
equivalent	NULL
population	NULL
of	NULL
cells	NULL
(	NULL
7	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
15	NULL
%	NULL
heat-inactivated	NULL
FCS	NULL
,	NULL
penicillin	NULL
,	NULL
and	NULL
streptomycin	NULL
.	NULL

Primary	NULL
B	NULL
cells	NULL
were	NULL
maintained	NULL
at	NULL
1	NULL
X	NULL
10°/	NULL
ml	NULL
;	NULL
LCL	NULL
#	NULL
3	NULL
cells	NULL
were	NULL
maintained	NULL
at	NULL
between	NULL
2	NULL
and	NULL
5	NULL
X	NULL
10°/ml	NULL
.	NULL

For	NULL
infection	NULL
experiments	NULL
,	NULL
EBV	NULL
was	NULL
purified	NULL
(	NULL
7	NULL
,	NULL
15	NULL
)	NULL
from	NULL
the	NULL
B95-8	NULL
cell	NULL
line	NULL
.	NULL

Its	NULL
integrity	NULL
was	NULL
checked	NULL
by	NULL
the	NULL
expression	NULL
of	NULL
viral	NULL
genes	NULL
or	NULL
by	NULL
the	NULL
ability	NULL
to	NULL
stimulate	NULL
DNA	NULL
synthesis	NULL
after	NULL
infection	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

B95-8	NULL
virus	NULL
was	NULL
added	NULL
to	NULL
primary	NULL
B	NULL
lymphocytes	NULL
at	NULL
saturating	NULL
levels	NULL
.	NULL

For	NULL
stimulation	NULL
assays	NULL
,	NULL
BU.1	NULL
(	NULL
anti	NULL
IgM	NULL
;	NULL
Ref	NULL
.	NULL

16	NULL
)	NULL
was	NULL
added	NULL
to	NULL
25	NULL
ug/ml	NULL
,	NULL
G25-8	NULL
(	NULL
anti-CDw40	NULL
;	NULL
Ref	NULL
.	NULL

17	NULL
)	NULL
was	NULL
added	NULL
to	NULL
1	NULL
ug/ml	NULL
,	NULL
and	NULL
IL-4	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
Poole	NULL
,	NULL
United	NULL
Kingdom	NULL
)	NULL
was	NULL
added	NULL
to	NULL
1000	NULL
units/ml	NULL
;	NULL
entry	NULL
of	NULL
cells	NULL
into	NULL
S	NULL
phase	NULL
was	NULL
confirmed	NULL
by	NULL
measuring	NULL
DNA	NULL
synthesis	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

RT-PCR	NULL
assays	NULL
.	NULL

Total	NULL
cell	NULL
RNA	NULL
was	NULL
routinely	NULL
prepared	NULL
from	NULL
1	NULL
X	NULL
10	NULL
'	NULL
cells	NULL
supplemented	NULL
with	NULL
100	NULL
ug	NULL
of	NULL
yeast	NULL
RNA	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
to	NULL
act	NULL
as	NULL
carrier	NULL
.	NULL

After	NULL
treatment	NULL
with	NULL
DNase-1	NULL
,	NULL
random	NULL
primed	NULL
cDNA	NULL
was	NULL
prepared	NULL
using	NULL
a	NULL
StrataScript	NULL
RT-PCR	NULL
kit	NULL
(	NULL
Stratagene	NULL
)	NULL
and	NULL
was	NULL
then	NULL
used	NULL
as	NULL
a	NULL
template	NULL
for	NULL
PCR	NULL
(	NULL
essentially	NULL
as	NULL
described	NULL
;	NULL
Ref	NULL
.	NULL

6	NULL
)	NULL
.	NULL

The	NULL
PCR	NULL
reaction	NULL
included	NULL
2	NULL
um	NULL
each	NULL
dNTP	NULL
supplemented	NULL
with	NULL
1	NULL
wCi	NULL
[	NULL
°P	NULL
]	NULL
dCTP	NULL
,	NULL
and	NULL
a	NULL
standard	NULL
thermocycle	NULL
profile	NULL
was	NULL
used	NULL
for	NULL
all	NULL
primer	NULL
sets	NULL
:	NULL
94°C	NULL
for	NULL
1	NULL
min	NULL
,	NULL
55°C	NULL
for	NULL
2	NULL
min	NULL
,	NULL
and	NULL
72°C	NULL
for	NULL
3	NULL
min	NULL
,	NULL
for	NULL
a	NULL
total	NULL
of	NULL
30	NULL
cycles	NULL
.	NULL

The	NULL
products	NULL
were	NULL
fractionated	NULL
on	NULL
a	NULL
6	NULL
%	NULL
denaturing	NULL
gel	NULL
and	NULL
visualized	NULL
by	NULL
autoradiography	NULL
.	NULL

The	NULL
size	NULL
of	NULL
each	NULL
gene	NULL
product	NULL
was	NULL
confirmed	NULL
by	NULL
comparison	NULL
with	NULL
DNA	NULL
size	NULL
markers	NULL
after	NULL
fraction-ation	NULL
on	NULL
a	NULL
50-cm	NULL
denaturing	NULL
gel	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
genes	NULL
included	NULL
members	NULL
of	NULL
the	NULL
cyclin	NULL
family	NULL
[	NULL
cyclin	NULL
D2	NULL
(	NULL
8	NULL
)	NULL
and	NULL
cyclin	NULL
E	NULL
(	NULL
18	NULL
)	NULL
]	NULL
,	NULL
the	NULL
prototypic	NULL
cdk	NULL
[	NULL
edc-2	NULL
(	NULL
19	NULL
)	NULL
]	NULL
,	NULL
growth-regulated	NULL
transcription	NULL
factors	NULL
[	NULL
c-myc	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
and	NULL
B-myb	NULL
(	NULL
22	NULL
)	NULL
)	NULL
,	NULL
and	NULL
the	NULL
FceRlIla	NULL
form	NULL
of	NULL
the	NULL
B-lymphocyte	NULL
activation	NULL
antigen	NULL
CD23	NULL
(	NULL
23-25	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
surface	NULL
receptor	NULL
CD44	NULL
(	NULL
26	NULL
)	NULL
and	NULL
the	NULL
ribosomal	NULL
phos-	NULL
4784	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1995	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

COMMON	NULL
PATHS	NULL
TO	NULL
CELL	NULL
CYCLE	NULL
ACTIVATION	NULL
Location	NULL
of	NULL
primers	NULL
for	NULL
RT-PCR	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Strategy	NULL
for	NULL
analysis	NULL
of	NULL
gene	NULL
expression	NULL
.	NULL

The	NULL
partial	NULL
structure	NULL
of	NULL
the	NULL
mRNA	NULL
transcripts	NULL
to	NULL
be	NULL
analyzed	NULL
are	NULL
shown	NULL
on	NULL
the	NULL
left	NULL
.	NULL

mRNA	NULL
;	NULL
thick	NULL
vertical	NULL
lines	NULL
,	NULL
position	NULL
of	NULL
known	NULL
splice	NULL
junctions	NULL
.	NULL

The	NULL
DNA	NULL
sequences	NULL
of	NULL
the	NULL
PCR	NULL
primers	NULL
used	NULL
to	NULL
amplify	NULL
each	NULL
gene	NULL
are	NULL
shown	NULL
on	NULL
the	NULL
right	NULL
;	NULL
--	NULL
-	NULL
»	NULL
,	NULL
position	NULL
of	NULL
the	NULL
PCR	NULL
product	NULL
.	NULL

phoprotein	NULL
36B4	NULL
(	NULL
27	NULL
)	NULL
were	NULL
used	NULL
as	NULL
controls	NULL
.	NULL

The	NULL
nucleotide	NULL
sequences	NULL
of	NULL
the	NULL
primers	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Results	NULL
and	NULL
Discussion	NULL
The	NULL
increase	NULL
in	NULL
the	NULL
level	NULL
of	NULL
cyclin	NULL
D2	NULL
mRNA	NULL
after	NULL
EBV	NULL
infection	NULL
of	NULL
primary	NULL
B	NULL
lymphocytes	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
at	NULL
least	NULL
100-fold	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
a	NULL
quantitative	NULL
RNase	NULL
protection	NULL
assays	NULL
(	NULL
7	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
explored	NULL
the	NULL
possibility	NULL
of	NULL
using	NULL
semiquantitative	NULL
RT-PCR	NULL
assays	NULL
to	NULL
detect	NULL
equivalent	NULL
changes	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
other	NULL
cell	NULL
cycle	NULL
genes	NULL
.	NULL

A	NULL
series	NULL
of	NULL
specific	NULL
primers	NULL
as	NULL
chosen	NULL
to	NULL
amplify	NULL
segments	NULL
of	NULL
each	NULL
gene	NULL
from	NULL
randomly	NULL
primed	NULL
cDNA	NULL
.	NULL

In	NULL
cases	NULL
where	NULL
the	NULL
genomic	NULL
organization	NULL
was	NULL
known	NULL
,	NULL
at	NULL
least	NULL
one	NULL
splice	NULL
junction	NULL
was	NULL
included	NULL
in	NULL
the	NULL
amplified	NULL
product	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

RNA	NULL
was	NULL
prepared	NULL
from	NULL
a	NULL
population	NULL
of	NULL
quiescent	NULL
primary	NULL
B	NULL
lymphocytes	NULL
isolated	NULL
from	NULL
peripheral	NULL
blood	NULL
by	NULL
positive	NULL
selection	NULL
(	NULL
7	NULL
,	NULL
15	NULL
)	NULL
and	NULL
from	NULL
a	NULL
continually	NULL
proliferating	NULL
cell	NULL
line	NULL
established	NULL
from	NULL
an	NULL
equivalent	NULL
population	NULL
of	NULL
cells	NULL
by	NULL
EBV-mediated	NULL
immortalization	NULL
(	NULL
LCL	NULL
#	NULL
3	NULL
;	NULL
Ref	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Using	NULL
RT-PCR	NULL
,	NULL
we	NULL
confirmed	NULL
that	NULL
the	NULL
two	NULL
control	NULL
genes	NULL
(	NULL
the	NULL
cell	NULL
surface	NULL
protein	NULL
CD44	NULL
and	NULL
the	NULL
ribosomal	NULL
phosphopro-tein	NULL
36B4	NULL
)	NULL
were	NULL
expressed	NULL
at	NULL
similar	NULL
levels	NULL
in	NULL
primary	NULL
B	NULL
lymphocytes	NULL
and	NULL
LCL	NULL
#	NULL
3	NULL
,	NULL
with	NULL
36B4	NULL
up-regulated	NULL
10-fold	NULL
after	NULL
immortalization	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

However	NULL
,	NULL
even	NULL
with	NULL
this	NULL
sensitive	NULL
assay	NULL
,	NULL
most	NULL
of	NULL
the	NULL
other	NULL
genes	NULL
were	NULL
not	NULL
expressed	NULL
at	NULL
detectable	NULL
levels	NULL
in	NULL
the	NULL
primary	NULL
B	NULL
lymphocytes	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
the	NULL
peripheral	NULL
B	NULL
lymphocytes	NULL
have	NULL
entered	NULL
into	NULL
G	NULL
,	NULL
and	NULL
thus	NULL
are	NULL
in	NULL
a	NULL
similar	NULL
state	NULL
of	NULL
quiescence	NULL
to	NULL
peripheral	NULL
T	NULL
cells	NULL
and	NULL
serum-starved	NULL
fibroblasts	NULL
.	NULL

The	NULL
only	NULL
exception	NULL
was	NULL
the	NULL
low	NULL
level	NULL
expression	NULL
of	NULL
c-myc	NULL
mRNA	NULL
,	NULL
in	NULL
line	NULL
with	NULL
a	NULL
previous	NULL
report	NULL
(	NULL
28	NULL
)	NULL
.	NULL

As	NULL
anticipated	NULL
,	NULL
c-myc	NULL
expression	NULL
was	NULL
up-regulated	NULL
at	NULL
least	NULL
10-fold	NULL
in	NULL
the	NULL
LCL	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
B-myb	NULL
mRNA	NULL
also	NULL
appeared	NULL
to	NULL
be	NULL
increased	NULL
by	NULL
at	NULL
least	NULL
10-fold	NULL
.	NULL

However	NULL
,	NULL
the	NULL
most	NULL
striking	NULL
differences	NULL
were	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
edc-2	NULL
,	NULL
cyclin	NULL
E	NULL
,	NULL
CD23	NULL
,	NULL
and	NULL
cyclin	NULL
D2	NULL
;	NULL
comparison	NULL
of	NULL
a	NULL
cDNA	NULL
dilution	NULL
series	NULL
suggested	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
these	NULL
genes	NULL
was	NULL
increased	NULL
at	NULL
least	NULL
100-fold	NULL
after	NULL
EBV-mediated	NULL
immortalization	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

The	NULL
magnitude	NULL
of	NULL
these	NULL
changes	NULL
in	NULL
gene	NULL
expression	NULL
,	NULL
together	NULL
with	NULL
the	NULL
ability	NULL
to	NULL
readily	NULL
detect	NULL
the	NULL
differences	NULL
using	NULL
RT-PCR	NULL
,	NULL
may	NULL
enable	NULL
us	NULL
to	NULL
investigate	NULL
the	NULL
effects	NULL
on	NULL
cell	NULL
cycle	NULL
progression	NULL
of	NULL
introducing	NULL
individual	NULL
EBV	NULL
genes	NULL
into	NULL
quiescent	NULL
primary	NULL
B	NULL
lymphocytes	NULL
(	NULL
7	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
it	NULL
will	NULL
be	NULL
interesting	NULL
to	NULL
investigate	NULL
the	NULL
direct	NULL
or	NULL
indirect	NULL
mechanisms	NULL
by	NULL
which	NULL
the	NULL
cell	NULL
genes	NULL
described	NULL
here	NULL
are	NULL
regulated	NULL
by	NULL
Size	NULL
Primer	NULL
sequences	NULL
231bp	NULL
5GGCTCTTGGAAATTGAGCGGAY	NULL
SAGGAACCCCTTCCTCTTCACT3	NULL
'	NULL
cyclin	NULL
E	NULL
--	NULL
-	NULL
234bp	NULL
sGCTTCTCcTCcTrecccaGTocect	NULL
x	NULL
5GCCCTGTTTGATGCCATCCACGAG3	NULL
'	NULL
cpr	NULL
220bp	NULL
sCCAGAGCTGTGATTGTGCCCG3	NULL
'	NULL
5GTGTCCCAGTGCCACAGGAGAY	NULL
'	NULL
c-mye	NULL
271bp	NULL
5'CCATGAATTACCTGGACCGTTTC3	NULL
SGTGGCACACAGAGCAATGAAGG3	NULL
'	NULL
cyclin	NULL
D2	NULL
_	NULL
330bp	NULL
SAAGATGTTGCCAGGGAGCGACAGY	NULL
5CCAGTTGGTCAGAAGACTTCCC3	NULL
201bp	NULL
STACCCTCTCAACGACAGCAGCTCGCCCAACTCCT3	NULL
5'GGCCTCCAGCAGAAGGTGATCCAGACTCTGACCT	NULL
»	NULL
480bp	NULL
5GACACATATTGCTTCAATGCTTCAG3	NULL
SGATGCCAAGATGATCAGCCATTCT3	NULL
'	NULL
180bp	NULL
5GGCCGAATTCTGTCTGTGGAGACGGATTACACCY	NULL
§GGCCGGATCCGACTCTTCCTTGGCTTCAACCITTAGY	NULL
'	NULL
input	NULL
cDNA	NULL
-	NULL
YPrimary	NULL
B-cell	NULL
LCL	NULL
#	NULL
3	NULL
dilution	NULL
--	NULL
-	NULL
ad	NULL
iG	NULL
edc-2	NULL
aa	NULL
%	NULL
a	NULL
cyclin	NULL
E	NULL
‘	NULL
0	NULL
‘	NULL
CD23	NULL
y	NULL
*¢e+	NULL
c-myc	NULL
&	NULL
&	NULL
«	NULL
=	NULL
cyclin	NULL
D2	NULL
*	NULL
B-myb	NULL
%	NULL
*	NULL
Q	NULL
,	NULL
*	NULL
CD44	NULL
t	NULL
4	NULL
4	NULL
+	NULL
C06	NULL
36B4	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Induction	NULL
of	NULL
gene	NULL
expression	NULL
after	NULL
EBV-mediated	NULL
immortalization	NULL
of	NULL
primary	NULL
B	NULL
lymphocytes	NULL
.	NULL

Total	NULL
cell	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
primary	NULL
peripheral	NULL
B	NULL
lymphocytes	NULL
and	NULL
a	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
(	NULL
LCL	NULL
#	NULL
3	NULL
)	NULL
.	NULL

RT-PCR	NULL
assays	NULL
for	NULL
the	NULL
indicated	NULL
genes	NULL
were	NULL
carried	NULL
out	NULL
on	NULL
a	NULL
cDNA	NULL
dilution	NULL
series	NULL
;	NULL
the	NULL
products	NULL
were	NULL
fractionated	NULL
on	NULL
a	NULL
6	NULL
%	NULL
denaturing	NULL
gel	NULL
and	NULL
visualized	NULL
by	NULL
autoradiography	NULL
.	NULL

4785	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1995	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

COMMON	NULL
PATHS	NULL
TO	NULL
CELL	NULL
CYCLE	NULL
ACTIVATION	NULL
EBV	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
CD23	NULL
and	NULL
cyclin	NULL
D2	NULL
are	NULL
regulated	NULL
by	NULL
EBV	NULL
genes	NULL
(	NULL
6-8	NULL
,	NULL
29	NULL
,	NULL
30	NULL
)	NULL
and	NULL
,	NULL
furthermore	NULL
,	NULL
that	NULL
the	NULL
increase	NULL
in	NULL
CD23	NULL
expression	NULL
involves	NULL
direct	NULL
transcriptional	NULL
regulation	NULL
via	NULL
an	NULL
EBNA-2	NULL
response	NULL
element	NULL
within	NULL
the	NULL
promoter	NULL
(	NULL
31	NULL
)	NULL
.	NULL

During	NULL
the	NULL
early	NULL
stages	NULL
of	NULL
EBV-mediated	NULL
immortalization	NULL
,	NULL
infected	NULL
cells	NULL
leave	NULL
G	NULL
,	NULL
,	NULL
and	NULL
take	NULL
3-4	NULL
days	NULL
to	NULL
progress	NULL
around	NULL
the	NULL
initial	NULL
cell	NULL
division	NULL
cycle	NULL
(	NULL
32-34	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
edc-2	NULL
,	NULL
cyclin	NULL
E	NULL
,	NULL
CD23	NULL
,	NULL
and	NULL
cyclin	NULL
D2	NULL
are	NULL
early	NULL
targets	NULL
for	NULL
EBV	NULL
,	NULL
we	NULL
investigated	NULL
their	NULL
expression	NULL
4	NULL
days	NULL
after	NULL
infection	NULL
with	NULL
EBV	NULL
.	NULL

36B4	NULL
mRNA	NULL
was	NULL
detected	NULL
in	NULL
both	NULL
infected	NULL
and	NULL
noninfected	NULL
cells	NULL
and	NULL
can	NULL
be	NULL
considered	NULL
as	NULL
a	NULL
control	NULL
for	NULL
imput	NULL
RNA	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Increased	NULL
expression	NULL
of	NULL
cedc-2	NULL
,	NULL
cyclin	NULL
E	NULL
,	NULL
CD23	NULL
,	NULL
and	NULL
cyclin	NULL
D2	NULL
all	NULL
occur	NULL
within	NULL
this	NULL
period	NULL
,	NULL
thus	NULL
,	NULL
the	NULL
up-regulation	NULL
of	NULL
these	NULL
genes	NULL
can	NULL
be	NULL
considered	NULL
as	NULL
events	NULL
that	NULL
occur	NULL
during	NULL
the	NULL
initial	NULL
cell	NULL
cycle	NULL
(	NULL
Table	NULL
1	NULL
and	NULL
Refs	NULL
.	NULL

7	NULL
and	NULL
28	NULL
)	NULL
.	NULL

The	NULL
normal	NULL
program	NULL
of	NULL
B-lymphocyte	NULL
cell	NULL
cycle	NULL
activation	NULL
can	NULL
be	NULL
mimicked	NULL
in	NULL
vitro	NULL
by	NULL
stimulating	NULL
quiescent	NULL
primary	NULL
B	NULL
lymphocytes	NULL
with	NULL
a	NULL
variety	NULL
of	NULL
agents	NULL
that	NULL
cause	NULL
limited	NULL
cell	NULL
proliferation	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

13	NULL
)	NULL
.	NULL

Because	NULL
several	NULL
features	NULL
of	NULL
this	NULL
program	NULL
are	NULL
common	NULL
to	NULL
the	NULL
early	NULL
stages	NULL
of	NULL
EBV-mediated	NULL
immortalization	NULL
(	NULL
32-34	NULL
)	NULL
,	NULL
we	NULL
explored	NULL
the	NULL
possibility	NULL
that	NULL
edc-2	NULL
,	NULL
cyclin	NULL
E	NULL
,	NULL
CD23	NULL
,	NULL
c-myc	NULL
,	NULL
and	NULL
cyclin	NULL
D2	NULL
may	NULL
also	NULL
be	NULL
up-regulated	NULL
during	NULL
this	NULL
process	NULL
.	NULL

We	NULL
therefore	NULL
investigated	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
same	NULL
genes	NULL
4	NULL
days	NULL
after	NULL
stimulation	NULL
of	NULL
quiescent	NULL
B	NULL
lymphocytes	NULL
with	NULL
a	NULL
cocktail	NULL
of	NULL
physiological	NULL
stimuli	NULL
(	NULL
anti-CD40	NULL
,	NULL
anti-IgM	NULL
,	NULL
and	NULL
IL-4	NULL
,	NULL
Ref	NULL
.	NULL

16	NULL
)	NULL
that	NULL
are	NULL
capable	NULL
of	NULL
driving	NULL
quiescent	NULL
B	NULL
lymphocytes	NULL
through	NULL
at	NULL
least	NULL
one	NULL
cell	NULL
cycle	NULL
.	NULL

36B4	NULL
mRNA	NULL
was	NULL
detected	NULL
in	NULL
both	NULL
stimulated	NULL
and	NULL
unstimulated	NULL
cells	NULL
,	NULL
but	NULL
cdc-2	NULL
,	NULL
cyclin	NULL
E	NULL
,	NULL
CD23	NULL
,	NULL
c-myc	NULL
,	NULL
and	NULL
cyclin	NULL
D2	NULL
mRNA	NULL
were	NULL
only	NULL
readily	NULL
detected	NULL
in	NULL
response	NULL
to	NULL
stimulation	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
investigated	NULL
changes	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
set	NULL
of	NULL
positive	NULL
regulators	NULL
of	NULL
cell	NULL
cycle	NULL
after	NULL
in	NULL
vitro	NULL
activation	NULL
with	NULL
either	NULL
physiological	NULL
stimuli	NULL
or	NULL
EBV	NULL
.	NULL

From	NULL
this	NULL
analysis	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
the	NULL
quiescent	NULL
status	NULL
of	NULL
peripheral	NULL
B	NULL
lymphocytes	NULL
is	NULL
maintained	NULL
,	NULL
in	NULL
part	NULL
,	NULL
by	NULL
the	NULL
lack	NULL
of	NULL
several	NULL
positive	NULL
regulators	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
show	NULL
that	NULL
the	NULL
same	NULL
set	NULL
of	NULL
cell	NULL
cycle	NULL
regulators	NULL
are	NULL
up-regulated	NULL
after	NULL
either	NULL
stimulation	NULL
with	NULL
anti-CD40	NULL
,	NULL
anti-IgM	NULL
,	NULL
and	NULL
IL-4	NULL
or	NULL
infection	NULL
with	NULL
EBV	NULL
(	NULL
Tables	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
with	NULL
the	NULL
observation	NULL
that	NULL
this	NULL
cocktail	NULL
of	NULL
physiological	NULL
stimuli	NULL
generates	NULL
cells	NULL
that	NULL
are	NULL
morphologically	NULL
indistinguishable	NULL
from	NULL
EBV-immortalized	NULL
LCLs	NULL
(	NULL
our	NULL
observations	NULL
and	NULL
Table	NULL
1	NULL
Cell	NULL
genes	NULL
induced	NULL
in	NULL
the	NULL
early	NULL
stages	NULL
of	NULL
EBV	NULL
infection	NULL
Infection	NULL
with	NULL
B95-8	NULL
EBV	NULL
'	NULL
Gene	NULL
(	NULL
-	NULL
)	NULL
(	NULL
+	NULL
)	NULL
cdc-2	NULL
-P	NULL
e	NULL
cyclin	NULL
E	NULL
-	NULL
+	NULL
CD23	NULL
-	NULL
+	NULL
cyclin	NULL
D2	NULL
-	NULL
+	NULL
36B4	NULL
+	NULL
+	NULL
``	NULL
Primary	NULL
B	NULL
lymphocytes	NULL
were	NULL
incubated	NULL
with	NULL
B95-8	NULL
EBV	NULL
where	NULL
indicated	NULL
and	NULL
harvested	NULL
after	NULL
4	NULL
days	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
the	NULL
indicated	NULL
cell	NULL
genes	NULL
was	NULL
determined	NULL
by	NULL
RT-PCR	NULL
assay	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Table	NULL
2	NULL
Cell	NULL
genes	NULL
induced	NULL
in	NULL
the	NULL
early	NULL
stages	NULL
of	NULL
B-lymphocyte	NULL
activation	NULL
Stimulation	NULL
with	NULL
physiological	NULL
agents	NULL
``	NULL
Gene	NULL
(	NULL
-	NULL
)	NULL
(	NULL
+	NULL
)	NULL
cdc-2	NULL
-	NULL
4°	NULL
cyclin	NULL
E	NULL
-	NULL
+	NULL
CD23	NULL
-	NULL
+	NULL
cyclin	NULL
D2	NULL
-	NULL
+	NULL
J6B4	NULL
+	NULL
+	NULL
``	NULL
Primary	NULL
B	NULL
lymphocytes	NULL
were	NULL
incubated	NULL
with	NULL
BU.1	NULL
,	NULL
G25-8	NULL
,	NULL
and	NULL
IL-4	NULL
where	NULL
indicated	NULL
and	NULL
harvested	NULL
after	NULL
4	NULL
days	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
the	NULL
indicated	NULL
cell	NULL
genes	NULL
was	NULL
determined	NULL
by	NULL
RT-PCR	NULL
assay	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Ref	NULL
.	NULL

13	NULL
)	NULL
,	NULL
this	NULL
provides	NULL
compelling	NULL
evidence	NULL
to	NULL
support	NULL
the	NULL
concept	NULL
that	NULL
EBV	NULL
exploits	NULL
the	NULL
normal	NULL
program	NULL
of	NULL
B-lymphocyte	NULL
cell	NULL
cycle	NULL
activation	NULL
as	NULL
part	NULL
of	NULL
its	NULL
strategy	NULL
to	NULL
infect	NULL
quiescent	NULL
cells	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Dr.	NULL
Louise	NULL
Brookes	NULL
for	NULL
advice	NULL
about	NULL
RT-PCR	NULL
and	NULL
Gordon	NULL
Peters	NULL
for	NULL
critical	NULL
review	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Weiss	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Littleman	NULL
,	NULL
D.	NULL
R.	NULL
Signal	NULL
transduction	NULL
by	NULL
lymphocyte	NULL
antigen	NULL
receptors	NULL
.	NULL

Cell	NULL
,	NULL
76	NULL
:	NULL
263-274	NULL
,	NULL
1994	NULL
.	NULL

2	NULL
.	NULL

Weinberg	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

The	NULL
retinoblastoma	NULL
protein	NULL
and	NULL
cell	NULL
cycle	NULL
control	NULL
.	NULL

Cell	NULL
,	NULL
87	NULL
:	NULL
323-330	NULL
,	NULL
1995	NULL
.	NULL

3	NULL
.	NULL

Peters	NULL
,	NULL
G.	NULL
Stifled	NULL
by	NULL
inhibitions	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
377	NULL
:	NULL
204-205	NULL
,	NULL
1994	NULL
.	NULL

4	NULL
.	NULL

Liebowitz	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Kieff	NULL
E.	NULL
,	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

/n	NULL
:	NULL
B.	NULL
Roizman	NULL
,	NULL
R.	NULL
Whiteley	NULL
,	NULL
and	NULL
C.	NULL
Lopez	NULL
(	NULL
eds	NULL
.	NULL
)	NULL

,	NULL
The	NULL
Human	NULL
Herpesviruses	NULL
,	NULL
pp	NULL
.	NULL

107-172	NULL
.	NULL

New	NULL
York	NULL
:	NULL
Raven	NULL
Press	NULL
,	NULL
1993	NULL
.	NULL

5	NULL
.	NULL

Kieff	NULL
,	NULL
E.	NULL
,	NULL
Izumi	NULL
K.	NULL
,	NULL
Kaye	NULL
,	NULL
K.	NULL
,	NULL
Longnecker	NULL
,	NULL
R.	NULL
,	NULL
Mannick	NULL
,	NULL
J.	NULL
,	NULL
Miller	NULL
,	NULL
C.	NULL
,	NULL
Robertson	NULL
,	NULL
E.	NULL
,	NULL
Swaminathan	NULL
,	NULL
S.	NULL
,	NULL
Tomkinson	NULL
,	NULL
B.	NULL
,	NULL
Tung	NULL
,	NULL
X.	NULL
,	NULL
and	NULL
Yalamanchili	NULL
,	NULL
R.	NULL
Specifically	NULL
mutated	NULL
Epstein-Barr	NULL
virus	NULL
recombinants	NULL
:	NULL
defining	NULL
the	NULL
minimal	NULL
genome	NULL
for	NULL
primary	NULL
B	NULL
lymphocyte	NULL
transformation	NULL
.	NULL

In	NULL
:	NULL
A.	NULL
Minson	NULL
and	NULL
J.	NULL
Neil	NULL
(	NULL
eds	NULL
.	NULL
)	NULL

,	NULL
Viruses	NULL
and	NULL
Cancer	NULL
,	NULL
pp	NULL
.	NULL

123-148	NULL
.	NULL

Cambridge	NULL
:	NULL
Cambridge	NULL
University	NULL
Press	NULL
.	NULL

1994	NULL
.	NULL

6	NULL
.	NULL

Sinclair	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Palmero	NULL
,	NULL
I.	NULL
,	NULL
Holder	NULL
,	NULL
A.	NULL
,	NULL
Peters	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Farrell	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

Expression	NULL
of	NULL
cyclin	NULL
D2	NULL
in	NULL
EBV	NULL
positive	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
lines	NULL
is	NULL
related	NULL
to	NULL
methylation	NULL
status	NULL
of	NULL
the	NULL
gene	NULL
.	NULL

J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
69	NULL
:	NULL
1292-1295	NULL
,	NULL
1995	NULL
.	NULL

7	NULL
.	NULL

Sinclair	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Palmero	NULL
,	NULL
I.	NULL
,	NULL
Peters	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Farrell	NULL
,	NULL
P.	NULL
J.	NULL
EBNA-2	NULL
and	NULL
EBNA-LP	NULL
co-operate	NULL
to	NULL
cause	NULL
G	NULL
,	NULL
to	NULL
G	NULL
;	NULL
transition	NULL
during	NULL
immortalisation	NULL
of	NULL
resting	NULL
human	NULL
B-lymphocytes	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
3	NULL
;	NULL
3321-3328	NULL
,	NULL
1994	NULL
.	NULL

8	NULL
.	NULL

Palmero	NULL
,	NULL
I.	NULL
,	NULL
Holder	NULL
,	NULL
A.	NULL
,	NULL
Sinclair	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Dickson	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Peters	NULL
,	NULL
G.	NULL
Cyclins	NULL
D1	NULL
and	NULL
D2	NULL
are	NULL
differentially	NULL
expressed	NULL
in	NULL
human	NULL
B-lymphoid	NULL
cell	NULL
lines	NULL
.	NULL

Oncogene	NULL
,	NULL
8	NULL
:	NULL
1049-1054	NULL
,	NULL
1993	NULL
.	NULL

9	NULL
.	NULL

Dractta	NULL
,	NULL
G.	NULL
F.	NULL
Mammalian	NULL
G	NULL
,	NULL
cyclins	NULL
.	NULL

Curt	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

,	NULL
6	NULL
:	NULL
842-846	NULL
,	NULL
1994	NULL
.	NULL

10	NULL
.	NULL

Peters	NULL
,	NULL
G.	NULL
the	NULL
D-type	NULL
cyclins	NULL
and	NULL
their	NULL
role	NULL
in	NULL
tumorigenesis	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Sci	NULL
.	NULL

78	NULL
(	NULL
Suppl	NULL
.	NULL
)	NULL

:	NULL
89-96	NULL
,	NULL
1994	NULL
.	NULL

11	NULL
.	NULL

Sherr	NULL
,	NULL
C.	NULL
Mammalian	NULL
G	NULL
;	NULL
cyclins	NULL
.	NULL

Cell	NULL
,	NULL
73	NULL
;	NULL
1059-1065	NULL
,	NULL
1993	NULL
.	NULL

12	NULL
.	NULL

Pardee	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
G	NULL
,	NULL
events	NULL
and	NULL
regulation	NULL
of	NULL
cell	NULL
proliferation	NULL
.	NULL

Science	NULL
(	NULL
Washington	NULL
DC	NULL
)	NULL
,	NULL
246	NULL
:	NULL
603-608	NULL
,	NULL
1989	NULL
.	NULL

13	NULL
.	NULL

Gordon	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Guy	NULL
,	NULL
G.	NULL
R.	NULL
The	NULL
molecules	NULL
controlling	NULL
B-lymphocytes	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
,	NULL
8	NULL
:	NULL
339-344	NULL
,	NULL
1987	NULL
.	NULL

14	NULL
.	NULL

Gordon	NULL
,	NULL
J.	NULL
B-cell	NULL
signalling	NULL
via	NULL
the	NULL
C-type	NULL
lectins	NULL
CD23	NULL
and	NULL
CD72	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
,	NULL
15	NULL
:	NULL
411-417	NULL
,	NULL
1994	NULL
.	NULL

15	NULL
.	NULL

Sinclair	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
and	NULL
Farrell	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

Methods	NULL
to	NULL
study	NULL
Epstein-Barr	NULL
virus	NULL
and	NULL
pS3	NULL
status	NULL
in	NULL
human	NULL
cells	NULL
.	NULL

/n	NULL
:	NULL
K.	NULL
W.	NULL
Aldolph	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Methods	NULL
in	NULL
Molecular	NULL
Genetics	NULL
,	NULL
pp	NULL
.	NULL

89-100	NULL
.	NULL

Orlando	NULL
,	NULL
FL	NULL
:	NULL
Academic	NULL
Press	NULL
,	NULL
1995	NULL
.	NULL

16	NULL
.	NULL

Gordon	NULL
,	NULL
J.	NULL
,	NULL
Millsum	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Flores-Romo	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Gillis	NULL
,	NULL
S.	NULL
Regulation	NULL
of	NULL
resting	NULL
and	NULL
cycling	NULL
human	NULL
B	NULL
lymphocytes	NULL
via	NULL
surface	NULL
IgM	NULL
and	NULL
the	NULL
accessory	NULL
molecules	NULL
inter-leukin-4	NULL
,	NULL
CD23	NULL
and	NULL
CD40	NULL
.	NULL

Immunology	NULL
,	NULL
68	NULL
:	NULL
526-531	NULL
,	NULL
1989	NULL
.	NULL

17	NULL
.	NULL

Clark	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
and	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Activation	NULL
of	NULL
human	NULL
B	NULL
cells	NULL
mediated	NULL
through	NULL
two	NULL
distinct	NULL
cell	NULL
surface	NULL
differentiation	NULL
antigens	NULL
Bp35	NULL
and	NULL
BpS50	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
83	NULL
:	NULL
4494-4497	NULL
,	NULL
1986	NULL
.	NULL

18	NULL
.	NULL

Koff	NULL
,	NULL
A.	NULL
,	NULL
Cross	NULL
,	NULL
F.	NULL
,	NULL
Fisher	NULL
,	NULL
A.	NULL
,	NULL
Schumacher	NULL
,	NULL
J.	NULL
,	NULL
Leguellec	NULL
,	NULL
K.	NULL
,	NULL
Philippe	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Roberts	NULL
,	NULL
J.	NULL
M.	NULL
Human	NULL
cyclin	NULL
E	NULL
,	NULL
a	NULL
new	NULL
cyclin	NULL
that	NULL
interacts	NULL
with	NULL
two	NULL
members	NULL
of	NULL
the	NULL
CDC2	NULL
gene	NULL
family	NULL
.	NULL

Cell	NULL
,	NULL
66	NULL
:	NULL
1217-1228	NULL
,	NULL
1991	NULL
.	NULL

19	NULL
.	NULL

Lee	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
and	NULL
Nurse	NULL
,	NULL
P.	NULL
Complementation	NULL
used	NULL
to	NULL
clone	NULL
a	NULL
human	NULL
homologue	NULL
of	NULL
the	NULL
fission	NULL
yeast	NULL
cell	NULL
cycle	NULL
control	NULL
gene	NULL
cdc-2	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
327	NULL
:	NULL
31-35	NULL
,	NULL
1987	NULL
.	NULL

20	NULL
.	NULL

Watt	NULL
,	NULL
R.	NULL
,	NULL
Stanton	NULL
,	NULL
L.	NULL
W.	NULL
,	NULL
Marcu	NULL
,	NULL
K.	NULL
B.	NULL
,	NULL
Gallo	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
Croce	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
and	NULL
Rovera	NULL
,	NULL
G.	NULL
Nucleotide	NULL
sequence	NULL
of	NULL
cloned	NULL
cDNA	NULL
of	NULL
human	NULL
c-myc	NULL
oncogene	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
303	NULL
:	NULL
725-728	NULL
,	NULL
1983	NULL
.	NULL

21	NULL
.	NULL

Battey	NULL
,	NULL
J.	NULL
,	NULL
Moulding	NULL
,	NULL
C.	NULL
,	NULL
Taub	NULL
,	NULL
R.	NULL
,	NULL
Murphy	NULL
,	NULL
W.	NULL
,	NULL
Stewart	NULL
,	NULL
T.	NULL
,	NULL
Potter	NULL
,	NULL
H.	NULL
,	NULL
Lenoir	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Leder	NULL
,	NULL
P.	NULL
The	NULL
human	NULL
c-myc	NULL
oncogene	NULL
:	NULL
structural	NULL
consequences	NULL
of	NULL
translocation	NULL
into	NULL
the	NULL
IgH	NULL
locus	NULL
in	NULL
Burkitt	NULL
lymphoma	NULL
.	NULL

Cell	NULL
,	NULL
34	NULL
:	NULL
779-787	NULL
,	NULL
1983	NULL
.	NULL

22	NULL
.	NULL

Nomura	NULL
,	NULL
N.	NULL
,	NULL
Takahashi	NULL
,	NULL
M.	NULL
,	NULL
Matsui	NULL
,	NULL
M.	NULL
,	NULL
Ishii	NULL
,	NULL
S.	NULL
,	NULL
Date	NULL
,	NULL
T.	NULL
,	NULL
Sasamoto	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Ishizaki	NULL
,	NULL
R.	NULL
Isolation	NULL
of	NULL
human	NULL
cDNA	NULL
clones	NULL
of	NULL
myb-related	NULL
genes	NULL
,	NULL
A-myb	NULL
and	NULL
B-myb	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
16	NULL
:	NULL
11075-11089	NULL
,	NULL
1988	NULL
.	NULL

23	NULL
.	NULL

Kikutani	NULL
,	NULL
H.	NULL
,	NULL
Inui	NULL
,	NULL
S.	NULL
,	NULL
Sato	NULL
,	NULL
R.	NULL
,	NULL
Barsumian	NULL
,	NULL
E.	NULL
L.	NULL
,	NULL
Owaki	NULL
,	NULL
H.	NULL
,	NULL
Yamasaki	NULL
,	NULL
K.	NULL
,	NULL
Kaisho	NULL
,	NULL
T.	NULL
,	NULL
Uchibayashi	NULL
,	NULL
N.	NULL
,	NULL
Hardy	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
Hirano	NULL
,	NULL
T.	NULL
,	NULL
Tsunasawa	NULL
,	NULL
S.	NULL
,	NULL
Suemura	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Kishimoto	NULL
,	NULL
T.	NULL
Molecular	NULL
structure	NULL
of	NULL
human	NULL
lymphocyte	NULL
receptor	NULL
for	NULL
immunoglobulin	NULL
E.	NULL
Cell	NULL
,	NULL
47	NULL
:	NULL
657-665	NULL
,	NULL
1986	NULL
.	NULL

24	NULL
.	NULL

Suter	NULL
,	NULL
U.	NULL
,	NULL
Bastos	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Hofstetter	NULL
,	NULL
H.	NULL
Molecular	NULL
structure	NULL
of	NULL
the	NULL
gene	NULL
and	NULL
the	NULL
5'-flanking	NULL
region	NULL
of	NULL
the	NULL
human	NULL
lymphocyte	NULL
immunoglobulin	NULL
E	NULL
receptor	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
15	NULL
;	NULL
7295-7308	NULL
,	NULL
1987	NULL
.	NULL

25	NULL
.	NULL

Yokota	NULL
,	NULL
A.	NULL
,	NULL
Kikutani	NULL
,	NULL
H.	NULL
,	NULL
Tanaka	NULL
,	NULL
T.	NULL
,	NULL
Sato	NULL
,	NULL
R.	NULL
,	NULL
Barsumian	NULL
,	NULL
E.	NULL
L.	NULL
,	NULL
Suemura	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Kishimoto	NULL
,	NULL
T.	NULL
Two	NULL
species	NULL
of	NULL
human	NULL
Fce	NULL
receptor	NULL
II	NULL
(	NULL
FeeRII/CD23	NULL
)	NULL
:	NULL
tissue-specific	NULL
and	NULL
IL-4-specific	NULL
regulation	NULL
of	NULL
gene	NULL
expression	NULL
.	NULL

Cell	NULL
,	NULL
55	NULL
:	NULL
611-618	NULL
,	NULL
1988	NULL
.	NULL

26	NULL
.	NULL

Screaton	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
Bell	NULL
,	NULL
M.	NULL
V.	NULL
,	NULL
Jackson	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
Cornelis	NULL
,	NULL
F.	NULL
B.	NULL
,	NULL
Gerth	NULL
,	NULL
U.	NULL
,	NULL
and	NULL
Bell	NULL
,	NULL
J.	NULL
I.	NULL
Genomic	NULL
structure	NULL
of	NULL
DNA	NULL
encoding	NULL
the	NULL
lymphocyte	NULL
homing	NULL
receptor	NULL
CD44	NULL
reveals	NULL
at	NULL
least	NULL
12	NULL
alternatively	NULL
spliced	NULL
exons	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
89	NULL
:	NULL
12160-12164	NULL
,	NULL
1992	NULL
.	NULL

27	NULL
.	NULL

Rich	NULL
,	NULL
B.	NULL
E.	NULL
,	NULL
and	NULL
Steitz	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

Human	NULL
acidic	NULL
ribosomal	NULL
phosphoproteins	NULL
PO	NULL
,	NULL
P1	NULL
,	NULL
and	NULL
P2	NULL
:	NULL
analysis	NULL
of	NULL
cDNA	NULL
clones	NULL
,	NULL
in	NULL
vitro	NULL
synthesis	NULL
,	NULL
and	NULL
assembly	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
7	NULL
:	NULL
4065-4074	NULL
,	NULL
1987	NULL
.	NULL

28	NULL
.	NULL

Alfieri	NULL
,	NULL
C.	NULL
,	NULL
Birkenbach	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Kieff	NULL
,	NULL
E.	NULL
Early	NULL
events	NULL
in	NULL
Epstein-Barr	NULL
virus	NULL
infection	NULL
of	NULL
human	NULL
B	NULL
lymphocytes	NULL
.	NULL

Virology	NULL
,	NULL
787	NULL
:	NULL
595-608	NULL
,	NULL
1991	NULL
.	NULL

4786	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1995	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

29	NULL
.	NULL

30	NULL
,	NULL
31	NULL
.	NULL

COMMON	NULL
PATHS	NULL
TO	NULL
CELL	NULL
CYCLE	NULL
ACTIVATION	NULL
Wang	NULL
,	NULL
F.	NULL
,	NULL
Gregory	NULL
,	NULL
C.	NULL
,	NULL
Sample	NULL
,	NULL
C.	NULL
,	NULL
Rowe	NULL
,	NULL
M.	NULL
,	NULL
Liebowitz	NULL
,	NULL
D.	NULL
,	NULL
Murray	NULL
,	NULL
R.	NULL
,	NULL
Rickinson	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Kieff	NULL
,	NULL
E.	NULL
Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein	NULL
(	NULL
LMP1	NULL
)	NULL
and	NULL
nuclear	NULL
proteins	NULL
2	NULL
and	NULL
3C	NULL
are	NULL
effectors	NULL
of	NULL
phenotypic	NULL
changes	NULL
in	NULL
B	NULL
lymphocytes	NULL
:	NULL
EBNA-2	NULL
and	NULL
LMP1	NULL
cooperatively	NULL
induce	NULL
CD23	NULL
.	NULL

J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
64	NULL
:	NULL
2309-2318	NULL
,	NULL
1990	NULL
.	NULL

Cordier	NULL
,	NULL
M.	NULL
,	NULL
Calender	NULL
,	NULL
A.	NULL
,	NULL
Billaud	NULL
,	NULL
M.	NULL
,	NULL
Zimber	NULL
,	NULL
U.	NULL
,	NULL
Rousselet	NULL
,	NULL
G.	NULL
,	NULL
Pavish	NULL
,	NULL
O.	NULL
,	NULL
Banchereau	NULL
,	NULL
J.	NULL
,	NULL
Turtz	NULL
,	NULL
T.	NULL
,	NULL
Bornkamm	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Lenoir	NULL
,	NULL
G.	NULL
M.	NULL
Stable	NULL
transfection	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
nuclear	NULL
antigen	NULL
2	NULL
in	NULL
lymphoma	NULL
cells	NULL
containing	NULL
the	NULL
EBV	NULL
P3HR1	NULL
genome	NULL
induces	NULL
expression	NULL
of	NULL
B-cell	NULL
activation	NULL
molecules	NULL
CD21	NULL
and	NULL
CD23	NULL
.	NULL

J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
64	NULL
:	NULL
1002-1013	NULL
,	NULL
1990	NULL
.	NULL

Wang	NULL
,	NULL
F.	NULL
,	NULL
Kikutani	NULL
,	NULL
H.	NULL
,	NULL
Tsang	NULL
,	NULL
S.	NULL
F.	NULL
,	NULL
Kishimoto	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Kieff	NULL
,	NULL
E.	NULL
Epstein-Barr	NULL
virus	NULL
32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

4787	NULL
nuclear	NULL
protein	NULL
2	NULL
transactivates	NULL
a	NULL
cis-acting	NULL
CD23	NULL
DNA	NULL
element	NULL
.	NULL

J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
65	NULL
:	NULL
4101-4106	NULL
,	NULL
1991	NULL
.	NULL

Thorley-Lawson	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
and	NULL
Mann	NULL
,	NULL
K.	NULL
P.	NULL
Early	NULL
events	NULL
in	NULL
Epstein-Barr	NULL
virus	NULL
infection	NULL
provide	NULL
a	NULL
model	NULL
for	NULL
B	NULL
cell	NULL
activation	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
162	NULL
:	NULL
45-59	NULL
,	NULL
1985	NULL
.	NULL

Gordon	NULL
,	NULL
J.	NULL
,	NULL
Walker	NULL
,	NULL
L.	NULL
,	NULL
Guy	NULL
,	NULL
G.	NULL
,	NULL
Brown	NULL
,	NULL
G.	NULL
,	NULL
Rowe	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Rickinson	NULL
,	NULL
A	NULL
.	NULL

Control	NULL
of	NULL
human	NULL
B-lymphocyte	NULL
replication	NULL
.	NULL

II	NULL
.	NULL

Transforming	NULL
Epstein-Barr	NULL
virus	NULL
exploits	NULL
three	NULL
distinct	NULL
viral	NULL
signals	NULL
to	NULL
undermine	NULL
three	NULL
separate	NULL
control	NULL
points	NULL
in	NULL
B-cell	NULL
growth	NULL
.	NULL

Immunology	NULL
,	NULL
58	NULL
:	NULL
591-595	NULL
,	NULL
1986	NULL
.	NULL

Walker	NULL
,	NULL
L.	NULL
,	NULL
Guy	NULL
,	NULL
G.	NULL
,	NULL
Brown	NULL
,	NULL
G.	NULL
,	NULL
Rowe	NULL
,	NULL
M.	NULL
,	NULL
Milner	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Gordon	NULL
,	NULL
G.	NULL
Control	NULL
of	NULL
human	NULL
B-lymphocyte	NULL
replication	NULL
.	NULL

Immunology	NULL
,	NULL
58	NULL
:	NULL
583-589	NULL
,	NULL
1986	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1995	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAGR	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Cancer	NULL
Research	NULL
The	NULL
Journal	NULL
of	NULL
Cancer	NULL
Research	NULL
(	NULL
1916-1930	NULL
)	NULL
|	NULL
The	NULL
American	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1931-1940	NULL
)	NULL
The	NULL
Normal	NULL
Cell	NULL
Cycle	NULL
Activation	NULL
Program	NULL
Is	NULL
Exploited	NULL
during	NULL
the	NULL
Infection	NULL
of	NULL
Quiescent	NULL
B	NULL
Lymphocytes	NULL
by	NULL
Epstein-Barr	NULL
Virus	NULL
Martine	NULL
Hollyoake	NULL
,	NULL
Albert	NULL
Stuhler	NULL
,	NULL
Paul	NULL
Farrell	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Cancer	NULL
Res	NULL
1995	NULL
;	NULL
55:4784-4787	NULL
.	NULL

Updated	NULL
version	NULL
_	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/55/21/4784	NULL
E-mail	NULL
alerts	NULL
_	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

Reprints	NULL
and	NULL
_	NULL
To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Subscriptions	NULL
_	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

Permissions	NULL
_	NULL
To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/55/21/4784	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1995	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

